NASDAQ:FIXXHomology Medicines Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Homology Medicines Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.64 +0.41 (+2.53 %) (As of 04/5/2020 03:57 AM ET) Add Compare Share Today's Range$15.18Now: $16.64▼$16.9650-Day Range$12.50MA: $16.78▼$22.0452-Week Range$11.05Now: $16.64▼$31.50Volume163,561 shsAverage Volume298,958 shsMarket Capitalization$752.13 millionP/E RatioN/ADividend YieldN/ABeta0.29 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingHomology Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.33, Homology Medicines has a potential upside of 100.3% from its current price of $16.64.Amount of Analyst CoverageHomology Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesHomology Medicines has received 86 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHomology Medicines has received 82 “underperform” votes. (Add your “underperform” vote.)Community SentimentHomology Medicines has received 51.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote “Outperform” if you believe FIXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,169,437.00 in company stock.Percentage Held by InsidersOnly 33.40% of the stock of Homology Medicines is held by insiders.Percentage Held by Institutions81.82% of the stock of Homology Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Homology Medicines are expected to decrease by -4.61% in the coming year, from ($2.82) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Homology Medicines is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Homology Medicines is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHomology Medicines has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.62 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FIXX Previous Symbol CUSIPN/A CIK1661998 Webhttp://www.homologymedicines.com/ Phone781-301-7277Debt Debt-to-Equity RatioN/A Current Ratio21.54 Quick Ratio21.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.67 million Price / Sales450.38 Cash FlowN/A Price / Cash FlowN/A Book Value$5.73 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)($2.47) Net Income$-103,920,000.00 Net Margins-6,237.46% Return on Equity-42.62% Return on Assets-34.60%Miscellaneous Employees124 Outstanding Shares45,200,000Market Cap$752.13 million Next Earnings Date5/11/2020 (Estimated) OptionableNot Optionable Receive FIXX News and Ratings via Email Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FIXX Rates by TradingView Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions How has Homology Medicines' stock been impacted by COVID-19 (Coronavirus)? Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FIXX stock has decreased by 7.1% and is now trading at $16.64. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Homology Medicines? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Homology Medicines. When is Homology Medicines' next earnings date? Homology Medicines is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Homology Medicines. How were Homology Medicines' earnings last quarter? Homology Medicines Inc (NASDAQ:FIXX) released its quarterly earnings results on Thursday, March, 12th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.13. The firm had revenue of $0.56 million for the quarter, compared to analysts' expectations of $0.40 million. Homology Medicines had a negative return on equity of 42.62% and a negative net margin of 6,237.46%. View Homology Medicines' earnings history. What price target have analysts set for FIXX? 7 Wall Street analysts have issued 1-year price targets for Homology Medicines' shares. Their forecasts range from $29.00 to $37.00. On average, they anticipate Homology Medicines' stock price to reach $33.33 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price. View analysts' price targets for Homology Medicines. Has Homology Medicines been receiving favorable news coverage? News articles about FIXX stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Homology Medicines earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutHomology Medicines. Are investors shorting Homology Medicines? Homology Medicines saw a decline in short interest in March. As of March 13th, there was short interest totaling 3,588,300 shares, a decline of 5.3% from the February 27th total of 3,790,000 shares. Based on an average trading volume of 366,500 shares, the short-interest ratio is presently 9.8 days. Currently, 17.1% of the company's stock are sold short. View Homology Medicines' Current Options Chain. Who are some of Homology Medicines' key competitors? Some companies that are related to Homology Medicines include Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), ArQule (ARQL), PPD (SDGR), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ra Pharmaceuticals (RARX), Alkermes (ALKS), Allakos (ALLK) and Arena Pharmaceuticals (ARNA). What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Inovio Pharmaceuticals (INO), Bank of America (BAC), Heron Therapeutics (HRTX), Stag Industrial (STAG), Gossamer Bio (GOSS), Nektar Therapeutics (NKTR) and Novavax (NVAX). Who are Homology Medicines' key executives? Homology Medicines' management team includes the following people: Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory BoardMr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63) When did Homology Medicines IPO? (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager. What is Homology Medicines' stock symbol? Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX." How do I buy shares of Homology Medicines? Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Homology Medicines' stock price today? One share of FIXX stock can currently be purchased for approximately $16.64. How big of a company is Homology Medicines? Homology Medicines has a market capitalization of $752.13 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe. View additional information about Homology Medicines. What is Homology Medicines' official website? The official website for Homology Medicines is http://www.homologymedicines.com/. How can I contact Homology Medicines? Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277. This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?
